Alle Studien
RekrutierungTherapeutische Bestätigung (Phase III)Interventionell

A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA, for the treatment of early onset Metachromatic Leukodystrophy (MLD)

This study is designed for children with early-onset Metachromatic Leukodystrophy (MLD) to confirm the effectiveness and safety of a gene therapy called Libmeldy. MLD is a rare genetic condition that affects the nervous system. The treatment involves using the child's own cells, which are specially modified in the lab, to help produce a missing enzyme. Researchers will primarily be tracking improvements in a child's ability to move and function over a period of 24 months after receiving the gene therapy. They will also be looking at overall health, changes in the brain, how the body responds to the treatment, and any potential side effects. The aim is to understand if this therapy can significantly improve the lives of children with MLD.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
Orchard Therapeutics (Europe) Limited
Einschreibeziel
10
Starten
20. Mai 2024

Worum geht es in dieser Studie?

This study is looking at a special type of treatment called gene therapy, known as Libmeldy, for children who have a condition called Metachromatic Leukodystrophy (MLD). MLD is a very rare and serious genetic disease that damages the brain and nervous system, affecting a child's ability to move, talk, and think over time. Currently, there are limited treatments available, so finding effective new options is extremely important.

The gene therapy in this study works by taking some of a child's own blood-forming stem cells, which are then carefully changed in a laboratory. These modified cells are designed to help the child's body produce a missing enzyme called Arylsulfatase A (ARSA). This enzyme is crucial for breaking down certain fats in the body; without it, these fats build up and cause damage to the brain and nerves.

The main goal of this study is to see how well Libmeldy helps children with MLD, especially in terms of their physical movement and overall health, over two years. Researchers will regularly check things like their ability to walk, stand, and balance. They will also monitor how the treatment affects their brain, nerves, and general well-being, while also keeping a very close eye on safety and any side effects. The hope is that this therapy can slow down or stop the progression of MLD and significantly improve the quality of life for these children.

Wichtige Erkenntnisse

  • This study is for children with early-onset Metachromatic Leukodystrophy (MLD).
  • It's testing a gene therapy called Libmeldy to see if it helps with movement and health.
  • The treatment involves a single infusion of specially modified cells.
  • Children in the study will be closely monitored for at least two years.
  • The main aim is to confirm the therapy's benefits and ensure its safety.

Wer könnte berechtigt sein?

This study is looking for children of all ages who have early-onset Metachromatic Leukodystrophy (MLD). This means the condition started at a young age.

Both boys and girls can take part in this study. The medical team will review each child's specific health details to make sure this treatment is suitable and safe for them. There might be other specific health requirements that your child needs to meet to be eligible for the study.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Does your child have a confirmed diagnosis of early-onset Metachromatic Leukodystrophy (MLD)?
  2. Is your child within an age range that the medical team believes suitable for the study?
  3. Is your child's overall health stable enough for them to potentially receive this treatment?
  4. Have you discussed your child's full medical history with the study team?
  5. Are you able to commit to regular follow-up appointments over at least two years?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

Taking part in this study would involve several visits to the clinic over a period of at least two years after receiving the gene therapy. You would likely have an initial assessment period to determine if your child is suitable. The treatment itself involves a single infusion of the Libmeldy cells. After the treatment, there will be regular check-ups where doctors will assess your child's movement, nerve function, and overall health. This will involve physical examinations, possibly some scans of the brain (like an MRI), and blood tests. They will also look for any side effects. The total duration of follow-up for some aspects could extend beyond two years to ensure long-term safety and effectiveness.

Potenzielle Risiken und Vorteile

Participating in this study might offer your child the chance to receive a cutting-edge gene therapy that could potentially slow down or stop the progression of MLD, improving their movement and overall health. However, like all medical treatments, there are potential risks and side effects, including those from the conditioning treatment needed before the gene therapy, and possible reactions to the infused cells. The study team will monitor your child very closely for any issues. It's important to remember that you have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

Standorte (1)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Italien

Häufige Fragen

What is MLD?

MLD, or Metachromatic Leukodystrophy, is a rare genetic disease that impacts the brain and nervous system, making it difficult for a child to move, speak, and think over time.

Was ist Gentherapie?

Gene therapy is a medical treatment that tries to correct the underlying cause of a disease by changing or replacing faulty genes in the body's cells.

How is Libmeldy given?

Libmeldy is given as a single infusion (like a drip) after your child has received a special preparation called 'conditioning regimen' to prepare their body for the new cells.

Wie lange wird die Studie dauern?

The main part of the study will track your child for at least 24 months (two years) after the treatment, with some assessments possibly continuing for longer to monitor long-term effects.

What will researchers be looking for?

Researchers will be primarily checking how your child's movement and physical abilities change over time. They will also monitor brain health, nerve function, and overall safety.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A single arm, open label, clinical study of cryopreserved au… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.